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A characteristic feature of hepatitis C virus (HCV) infection is a high frequency of persistence and the progression to
chronic liver diseases. Recent data suggest that prevalent T helper (Th) 2 immunity as well as weak HCV-specific T-cell
response is associated with viral persistence. Here, we showed that the production of interleukin 12 (IL-12) and nitric oxide
(NO) that is critical for the induction of Th1 and innate immunity, but not that of tumor necrosis factor a (TNF-a), was
significantly suppressed in both HCV core-expressing macrophage cell lines and mouse peritoneal macrophages treated
with recombinant core protein. In addition, IL-12 p40 promoter activity was repressed by the presence of HCV core in
macrophages stimulated with lipopolysaccharride (LPS) following IFN-g treatment, indicating that IL-12 production may be
downregulated at the transcriptional level. We also found that proliferation of T cells and IFN-g production in mixed
lymphocyte reactions (MLR) with core-expressing cells were inhibited. Taken together, our results suggest that HCV core
protein could play roles in suppressing the induction of Th1 immunity through inhibition of IL-12 and NO production. © 2001
Academic Press
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Hepatitis C virus (HCV) is a positive-strand RNA virus
belonging to the flaviviridae family and chronically in-
fects about 170 million person worldwide. HCV infection
induces a high frequency of persistence (up to 85% of
acute infection) and the progression to chronic liver dis-
eases, including cirrhosis and hepatocellular carcinoma
(HCC) (Cohen, 1999). The failure of a host immune re-
sponse to eliminate HCV has been mainly explained by
rapid generation of viral variants (Farci et al., 2000) and
weak immunogenicity resulting from the low level of viral
replication (Christie et al., 1999) and the replication of the
irus in the immune-privileged sites of the body. Alterna-
ively, HCV clearance by host can be inhibited by HCV
ene products such as envelope protein 2 (E2) and
onstructural (NS) 5 proteins, which interact with double-
tranded RNA-activated protein kinase (PKR) to inhibit
ntiviral activity of interferon a (IFN-a) (Song et al., 1999;
Taylor et al., 1999).
These explanations, however, are insufficient to ac-
count for recent evidence that weak T cell responses and
a prevalent Th2 pattern of cytokine production are asso-
ciated with persistence of HCV and chronic evolution of
diseases (Diepolder et al., 1995; Missale et al., 1996; Tsai
et al., 1997). In general, the differentiation of naive CD41
T helper (Th0) cells into Th1 or Th2 cells is often decisive
for the outcome of a lot of diseases, and the polarization1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 82-54-279-5544. E-mail: ycsung@postech.ac.kr.
271of Th subtypes depends on the costimulatory attributes
of the antigen-presenting cells (APCs) as well as the
nature and abundance of cytokines provided by them at
the initiation of immune response. It was reported that
the level of IFN-g was extremely low in the mixed lym-
phocyte reaction (MLR) with the dendritic cells (DCs),
one of APCs, from HCV patients (Kanto et al., 1999) and
hat patients with chronic hepatitis C have a lower fre-
uency of HCV core-reactive IFN-g-producing T cells
compared with that of anti-HCV positive healthy subjects
(Lechmann et al., 1996; Woitas et al., 1996). In addition,
lymphoid DCs expressing HCV structural genes were
demonstrated to have the impaired allostimulatory ca-
pacity (Hiasa et al., 1998). These data suggest that HCV
ene products could play a role in the dysfunction of
PCs, leading to defective cellular immunity including
CV-specific Th1 and cytotoxic T lymphocyte (CTL) re-
ponses. Therefore, it is necessary to investigate which
CV gene products are involved in the negative regula-
ion of APCs’ function.
In this study, we focused on the effect of HCV core
rotein on the function of macrophages because there
re increased mortality, depressed production of IFN-g
and IL-2, and suppression of vaccinia-specific CTL re-
sponse in mice inoculated with recombinant vaccinia/
HCV core virus (Large et al., 1999). Moreover, HCV core
protein was known to be a highly conserved protein
among HCV gene products and has many functions such
as transcriptional regulation of several genes and mod-
ulation of cell growth and apoptosis, in addition to its role
in viral morphogenesis (Ray et al., 1995, 1997, 1998;
0042-6822/01 $35.00
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272 LEE ET AL.Srinivas et al., 1996; Chang et al., 1998; Zhu et al., 1998).
ere, we found that production of IL-12 and NO, but not
f TNF-a, was dramatically suppressed in core-express-
ing macrophages and DCs as well as in macrophages
treated with recombinant core protein produced in E.
coli. In addition, the stimulatory capacity of macrophages
in MLR was demonstrated to be impaired by the pres-
ence of core protein.
RESULTS
The production of IL-12 and NO, but not TNF-a, was
significantly reduced in HCV core-expressing
macrophages compared with their control cells
To examine whether HCV core protein has any effects
on the function of APCs, we established in vitro tissue
culture systems in which HCV core was expressed in
macrophage cell lines. Murine macrophage cell lines,
RAW 264.7 and J774 cells, and human promonocytic cell
line, THP-1 cells, were stably transfected with pCI-Neo/
core 1–191 encoding the full length of HCV core protein.
Through immunoblotting analysis with rabbit anti-HCV
core antibody, RAW 264.7/Core, J774/Core, and THP-1/
Core were isolated (data not shown). Cells transfected
with pCI-Neo vector, RAW 264.7/Neo, J774/Neo, and THP-
1/Neo were also established to use as negative controls.
The established macrophage cells were stimulated with
LPS (5 mg/ml, 30 h) following pretreatment of recombi-
ant IFN-g (1000 U/ml, 8 h), and then the amount of IL-12
n the supernatants of the activated macrophages was
easured through ELISA. As shown in Fig. 1A, core-
xpressing macrophages RAW 264.7/Core and J774/Core
howed marked reduction of IL-12 secretion in response
o IFN-g and LPS treatment, whereas RAW 264.7/Neo
and J774/Neo yielded 450 and 100 pg/ml of IL-12 produc-
tion, respectively.
To exclude the possibility that the responsiveness of
core-expressing macrophage cells to LPS could be mod-
ified in the process of establishing stable cell lines, RAW
264.7/Neo and RAW 264.7/Core cells were also stimu-
lated with other stimulants such as zymosan and p1826.
Zymosan is a ghost yeast cell that is a kind of particle to
be phagocytosed by macrophages, and p1826, CpG mo-
tif-containing oligodeoxynucleotide, is known to have an
immunostimulatory capacity (Yi et al., 1998). In these
xperiments, we also observed the dramatic suppres-
ion of IL-12 production when core-expressing macro-
hage cells were stimulated with either zymosan or
1826. These results suggest that the inhibitory effect of
CV core protein on IL-12 production from activated
acrophages is stimulant-independent. In contrast,
NF-a production from RAW 264.7/Core or J774/Core was
almost equal to that from their control cells (Fig. 1A),
reinforcing that HCV core protein caused the impairment
of IL-12 production from activated macrophage cells
without the general unresponsiveness to various stimu-lants. These results are partially consistent with a recent
clinical observation that DCs from HCV-infected patients
showed a low allogeneic capacity with no sign of a
generalized immune suppression (Kanto et al., 1999).
NO also has been known to play a major role in the
ffector phase of the Th1 response as well as to be
equired for IL-12 signaling in innate immunity (Holscher
t al., 1998; Diefenbach et al., 1999; Bogdan et al., 2000).
So, we measured the level of NO accumulated during the
activation of macrophages (Fig. 1A). Treatment of RAW
264.7/Neo and J774/Neo cells with three different stimu-
lants led to the accumulation of 20 to 40 mM NO within
24 h. However, the concentration of NO released from
RAW 264.7/Core and J774/Core was as low as 5 mM,
indicating that HCV core protein downregulates NO re-
lease as well as IL-12 production. The suppression of
both IL-12 and NO secretion by HCV core protein was
also observed in human promonocytic cells. IL-12 and
NO production from THP-1/Core cells were significantly
reduced compared with that from THP-1/Neo, a control
cell (Fig. 1B).
To further confirm our observations, we isolated
splenic DCs of transgenic mice carrying HCV core gene
under the control of a transcriptional regulatory region
from hepatitis B virus. HCV core protein was detectable
in the splenic monocytes of transgenic mice as well as in
the liver and kidney by Western blot analysis (data not
shown). Consistent with our previous results, IL-12 se-
cretion from splenic DCs of transgenic mice treated with
IFN-g and LPS was significantly suppressed compared
with that from splenic DCs of nontransgenic littermate
mice of the same age (Fig. 1C). However, the level of
TNF-a production was similar in both mice, indicating
that HCV core protein can exert its inhibitory effect on the
function of splenic DCs in terms of IL-12 production.
The suppression by HCV core protein was dose-
dependent and occurred at the transcriptional level
To determine whether the suppression of IL-12 and NO
production is related with the expression level of core
protein, we isolated several clones of RAW 264.7/Core
cells with different expression levels (Fig. 2A). After ac-
tivation with either LPS or zymosan in the presence or
absence of IFN-g pretreatment, IL-12 and NO released
into supernatants were measured. We found that IL-12
and NO productions were further suppressed at higher
concentrations of core protein (Fig. 2B). In contrast, the
complete repression of NO production from RAW 264.7/
Core clones after zymosan treatment was achieved with
the lowest concentration of core protein. Since IL-12 and
NO inductions were markedly suppressed in different
clones of macrophage cells and operative in RAW 264.7/
Core (L), which produces core protein about 20-fold
lower than that of RAW/Core (H) (Fig. 2B), it is unlikely
that the results observed here are an artifact caused by
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273HCV CORE PROTEIN INHIBITS PRODUCTION OF IL-12 AND NOthe positional effect of the integrated DNA and/or the
overexpression of core in the cell line in vitro.
Having established the specificity of the HCV core
effect upon the production of IL-12, we further confirmed
the downregulation of IL-12 production by HCV core
protein at the transcription level. IL-12 p40-luciferase
construct (Fig. 3A) was transiently cotransfected into
RAW 264.7/Neo and RAW 264.7/Core cells together with
b-galactosidase expressing vector as an internal control.
As shown in Fig. 3B, when the transfected cells were
FIG. 1. Inhibition of IL-12 and NO production, but not TNF-a, in the va
ore-expressing macrophages [RAW 264.7/Core (H) and J774/Core] and
mg/ml), zymosan (100 mg/ml), or p1826 (10 mg/ml) for 30 h, following the
r p1826 were treated at the same condition as described above witho
sing the cultured supernatants from activated macrophage cells. NO
xcept that J774 cells were stimulated with IFN-g and LPS. (B) After activ
nd THP-1/Core cells was measured. (C) DCs derived from the splenic m
ctivated with IFN-g and LPS. Production of IL-12 and TNF-a from th
littermates of the same age were used as controls. The values repre
respectively.stimulated with IFN-g (1000 U/ml, 8 h) and LPS (5 mg/ml,
8 h), IL-12 p40 promoter-driven luciferase activity wasmarkedly decreased in RAW 264.7/Core compared with
that in RAW 264.7/Neo. This observation implicates that
IL-12 production from HCV core-expressing RAW 264.7
cells may be transcriptionally downregulated.
NO production from mouse peritoneal macrophages,
but not TNF-a, was suppressed by the exogenous
addition of purified core protein
Evidence of the existence of extrahepatic sites sup-
acrophages expressing HCV core gene. (A) For the induction of IL-12,
ontrol cells (RAW 264.7/Neo and J774/Neo) were stimulated by LPS (5
retreatment (1000 U/ml, 8 h). For the induction of TNF-a, LPS, zymosan,
g pretreatment. IL-12 and TNF-a production were measured by ELISA
ion was determined using Griess reagent after LPS stimulation (24 h),
nder the same conditions, production of IL-12 and NO from THP-1/Neo
tes of transgenic mice (8-week-old) expressing HCV core protein were
lls was measured through ELISA. The splenic DCs of nontransgenic
e averages of assay from three transgenic and nontransgenic mice,rious m
their c
IFN-g p
ut IFN-
product
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ese ceporting HCV replication continues to accumulate
(Wang et al., 1992; Lerat et al., 1996; Laskus et al.,
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274 LEE ET AL.2000). Detection of HCV genomic sequences, both the
positive- and the negative-strand RNA, from monocyte/
macrophage that is one of the pheripheral blood
mononuclear cell (PBMC)-associated cell subsets,
was previously reported (Bouffard et al., 1992; Gabrielli
et al., 1994; Lerat et al., 1998). So, it is possible that
HCV core protein expressed within APCs during rep-
lication exerts its inhibitory effect on function of APCs.
Alternatively, APCs such as macrophages and DCs
may take up viral particles and/or core proteins re-
leased from damaged hepatocytes. To investigate
whether HCV core protein by itself could be taken by
APCs, presumably through endocytosis, and then dys-
regulate the function of APCs, we added recombinant
core protein to the mouse peritoneal macrophages,
and then measured the level of NO. Recombinant core
protein that was overexpressed in E. coli and purified
with more than 95% homogeneity was used for this
study (data not shown). Interestingly, NO release, but
not TNF-a production from LPS-stimulated peritoneal
macrophages was dramatically inhibited by preincu-
bation with 20 mg/ml of exogenous core protein for 1 h.
FIG. 2. Dose-dependent suppression of IL-12 and NO productions in H
264.7/Core clones were compared by immunoblotting with anti-HCV cor
expressing the highest level of core protein. RAW 264.7/Core (M) and R
level of HCV core protein compared with that of RAW 264.7/Core (H), re
264.7/Core clones, represented as low (L), medium (M), and high (H), a
performed as described in Fig. 1.CV-core-expressing cells. (A) Core expression levels from three different RAW
e antisera. Among the isolated clones, RAW 264.7/Core (H) represents a clone
AW 264.7/Core (L) represent clones with medium and the lowest expression
spectively. (B) Production of NO and IL-12 was compared among several RAWowever, heat-inactivated core protein or control
uffer did not suppress NO production (Fig. 4), sup-
r
fFIG. 3. The repression of IL-12 p40 promoter activity in HCV core-
expressing RAW 264.7 cells. (A) The IL-12 p40 promoter-luciferase
plasmid, pGL2-p40/Luc, which contains 3.6 kb of upstream region of
IL-12 p40 transcription start site, was constructed. (B) The pGL2-p40/
Luc (20 mg) and pRC/CMV b-Gal (5 mg), b-galactosidase expression
vector as an internal control, were transiently cotransfected into the
various macrophage cell lines (5 3 106) by electroporation. After 24 h,
cells were stimulated with IFN-g (1000 U/ml, 8 h) and LPS (5 mg/ml, 8 h),
nd cell extracts were prepared with 100 ml of lysis buffer (20 mM
EPES, pH 7.2, 150 mM NaCl, 1% Triton X-100, 10% glycerol). The
alues shown are based on the activity of pGL2-p40/Luc (luciferase)
elative to that of pRc/CMV-b-gal (b-galactosidase) and are averages of
ive independent experiments.
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275HCV CORE PROTEIN INHIBITS PRODUCTION OF IL-12 AND NOporting that exogenous core protein also exerts its
inhibitory effect on the function of peritoneal macro-
phages.
FIG. 4. Inhibition of NO production from mouse peritoneal macro-
phages, but not TNF-a, by exogenous HCV core protein. Mouse peritoneal
acrophages were prepared from 8- to 10-week-old BALB/c mice. The
rimary macrophages (0.5 to 1 3 106) were stimulated either with or
without LPS (5 mg/ml) for 20 h after preincubation with control buffer (PBS
ith 0.1% Triton X-100, 1 mM EDTA, and 1 mM DTT), core protein (2 mg/ml),
or heat-inactivated (HI) core protein (2 mg/ml) for 1 h. TNF-a production
nd nitrate accumulation in culture medium were measured.
FIG. 5. Impaired allostimulatory capacity and reduced IFN-g produc
ncorporated into primary human T cells (1 to 2 3 106 cells) cocultured
The stimulation index (SI) was defined as the ratio of cpm betwee
macrophages. Con A (5 mg/ml)-stimulated T cells were used as positive
ubjects were shown to be similar. The data shown here represent the
roduction of IFN-g from MLR was measured through ELISA using the sculture were stained with FITC-conjugated Annexin V (10 mg/106 cells). Annex
ines indicate the cells with THP-1/Core and with THP-1/Neo from MLR, respTHP-1/Core cells showed impaired allostimulatory
capacity and reduced IFN-g production in MLR
To examine the effect of core protein on the allostimu-
latory capacity of macrophages in MLR, both THP-1/Core
and THP-1/Neo cells as a negative control were treated
with 5 mg/ml of LPS for 24 h after pretreatment of 1000
U/ml IFN-g for 8 h, and then used as stimulators to
activate purified CD31 primary human T cells. After 5
days of coculture, the degree of T-cell proliferation and
cytokine production were measured. Thymidine incorpo-
ration and the production of IFN-g were markedly lower
in MLR with THP-1/Core than in that with THP-1/Neo at
two different ratios of primary human T cells to DNA-
transfected THP-1 cells (Figs. 5A and 5B), indicating that
HCV core protein is associated with defective function of
macrophages. Since the reduced allostimulatory poten-
tial of THP-1/Core could be the result of the enhanced
apoptosis of primary T cells during MLR, the cells at Day
macrophages expressing HCV core. (A) The amount of [3H]thymidine
HP-1/Core or THP-1/Neo cells (2 3 106 cells) in MLRs was measured.
amples with stimulated macrophages and those with unstimulated
ls. The results from three independent assays using T cells from three
ges in triplicate cultures with T cells from one of the subjects. (B) The
tants harvested on Day 5. (C) The cells recovered on Day 5 in the MLRtion of
with T
n the s
contro
avera
uperna
in V-bound cells were assessed using FACS analysis. Thick and thin
ectively.
276 LEE ET AL.5 of MLR were stained with FITC–Annexin V. Flow cyto-
metric analysis showed a similar profile in the Annexin
V-positive macrophages and T cells after cocultures with
either THP-1/Neo or THP-1/Core (Fig. 5C), suggesting
that downmodulation of T cell proliferation and IFN-g
production by core protein did not result from the sus-
ceptibility or inducibility of apoptosis. Furthermore, to
rule out the possibility that HCV core protein exerts its
suppressive effects on IL-12 and NO production via the
secretion of antiinflammatory cytokine such as IL-10, we
measured IL-10 production from DNA-transfected mac-
rophages in response to various stimulations, but could
not detect any significant change of IL-10 production in
the same conditions tested (data not shown). Thus, these
results suggest that HCV core protein could downregu-
late the allostimulatory capacity of macrophages, which
is independent on the proapoptosis or upregulation of
antiinflammatory cytokine.
DISCUSSION
The present study demonstrated that HCV core pro-
tein, which is either expressed within macrophage cells
or exogenously added to them, is capable of suppress-
ing production of IL-12 and NO, but not of TNF-a, from
APCs treated with IFN-g and LPS. In addition, HCV core
protein was shown to exert an inhibitory effect on the
stimulatory capacity of macrophages in MLR. These re-
sults are partially consistent with the following observa-
tions that the allostimulatory capacity of peripheral DCs
recovered from chronic hepatitis C patients was im-
paired (Kanto et al., 1999) and that lymphoid DCs ex-
pressing structural genes of HCV have a lower stimula-
tory capacity (Hiasa et al., 1998). It has been known that
IL-12 promotes cell-mediated immunity by facilitating Th1
responses, including IFN-g production from both T and
NK cells, enhances the lytic activity of NK cells, and
augments specific CTL responses (Trinchieri, 1994).
Some viruses such as human immunodeficiency virus
(HIV) and measles virus (MV) were reported to inhibit the
secretion of IL-12 from PBMC and/or APC, which appear
to be one of the strategies to evade host immune re-
sponse, even though exact molecular mechanisms are
still unclear (Clerici et al., 1993; Karp et al., 1996).
Other viruses encode viral gene products that are able
to cause cytokine imbalance. For example, Epstein–Barr
virus encodes BCRF-1, an IL-10 homolog which sup-
presses cytokine production from the Th1 subset like
IL-10 (Moore et al., 1990). This strategy can give the virus
a distinct advantage, helping it to evade host immune
defenses by inhibiting the generation of effective antiviral
immunity. Since HCV core protein was known to be a
structural capsid protein, it raises an interesting question
about the biological role of core protein. It was recently
reported that HCV core protein functions as a Raf-1
kinase-activating protein through its interaction with 14-3-3 protein (Aoki et al., 2000). Raf-1 activation by core
protein resulted in the extracellular signal-related ki-
nase (ERK) activation, which may lead to the suppres-
sion of IL-12 production. In addition, it was reported
that p38 mitogen-activated protein (MAP) kinase is
required for the induction of IL-12 p40 mRNA, and that
macrophages and DCs from Mkk3(2/2) mice showed
defective production of IL-12 (Feng et al., 1999; Lu et
al., 1999). Therefore, it is likely that the direct or indi-
rect interference of Raf-1 and/or p38 MAPK by HCV
core protein may be possible mechanisms involved in
the suppression of the IL-12 production. As a prelim-
inary result, we demonstrated that phosphorylation of
p38 MAPK in macrophages stimulated with LPS was
significantly reduced by both endogenous and exoge-
nous core proteins, although that of ERK was not
affected by HCV core protein (our unpublished re-
sults). These results are similar to the effect of p15E, a
retroviral envelope protein, in terms of inhibition of
signal transduction by viral structural protein, leading
to negative regulation of the host immune responses.
The p15E protein was known to block signal transduc-
tion by protein kinase C during T cell activation (Dez-
zutti et al., 1990; Ruegg et al., 1990).
It is of interest to note that recombinant core protein
that was exogenously added to APCs can downregulate
NO production, but not that of TNF-a. A few recombinant
proteins such as HIV-1 Tat and human formy virus Bel-1
are known to have biological activity when these pro-
teins were treated to cells (Lee et al., 1994; Chen et al.,
1997; Gibellini et al., 1998; Kumar et al., 1998). However,
it is still an open question how exogenous recombinant
protein enters cells to exert its biological activities. What-
ever the mechanisms are, our results provide a new
insight that HCV is capable of suppressing Th1 immunity
through downregulation of IL-12 production presumably
by core protein released from either broken hepatocytes
or extrahepatic reservoirs such as PBMCs and viral
particles, in spite of lack of endogenous synthesis in
APCs.
In addition to core protein, HCV has been known to
encode E2 and NS5A proteins that inactivate PKR (Song
et al., 1999; Taylor et al., 1999), which may overcome the
antiviral effect of the interferon, a major nonspecific host
defense against viruses. Recent observation that the
production of IL-12 and IFN-g in patients with viremic
chronic hepatitis C is weaker than that in control sub-
jects suggests that defective production of IL-12 and
IFN-g may contribute to the persistence of HCV infection
(Sarih et al., 2000). Therefore, together with the previous
reports about the function of HCV E2 and NS5A protein,
our results may provide possible explanations about the
establishment and maintenance of high persistent HCV
infection in humans.
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Cell lines and plasmid
The murine macrophagic cell lines RAW 264.7 and
J774, and the human promonocytic cell line THP-1 were
purchased from American Type Culture Collection
(ATCC, Rockville, MD) and maintained in Dulbecco’s
modified Eagle’s medium (Gibco BRL, Gaithersburg, MD)
and RPMI 1640 (Gibco BRL) supplemented with 10% fetal
calf serum (HyClone, Logan, UT), respectively. Plasmid
pCI-Neo/core 1–191 encoding the full length of HCV core
protein was constructed by inserting the PCR-amplified
core region of the HCV-K isolate (genotype 1b) into the
eukaryotic expression vector pCI-Neo (Promega, Madi-
son, WI).
Establishment of stable cell lines expressing HCV
core protein
For stable expression of the HCV core protein, pCI-
Neo/core 1–191 was transfected into RAW 264.7, J774,
and THP-1 cells by the electroporation method as previ-
ously described (Ma et al., 1997), after which transfected
cells were isolated as each of single clones. Briefly, cells
were collected and washed once with serum-free media,
and resuspended in the complete media containing 10%
serum at a concentration of 2 3 106 cells/250 ml. Cell
uspension (250 ml) and plasmid DNA (20 mg) were
placed in 0.45-cm electroporation cuvettes (Gene Pulser;
Bio-Rad Laboratories, Richmond, CA) and electropora-
tion was carried out at 960 mF and 250 V. Transfected
cells were selected with 400 mg/ml (for RAW 264.7 and
774 cells) or 700 mg/ml (for THP-1 cells) of G418 sulfate
(Gibco BRL). After 2 weeks of selection, several clones
were isolated and whole cell lysates of each clone were
immunoblotted with rabbit anti-HCV core antibody. Sta-
ble cell clones transfected with empty vector, pCI-Neo,
were also established to serve as controls. All of the
permanent cell clones were maintained in the presence
of G418 sulfate (200 mg/ml) throughout the experiment.
Reagents
Human and murine IFN-g were purchased from R&D
Systems (Minneapolis, MN), and LPS (Escherichia coli
0127:B8) was purchased from Sigma Chemical Co. (St.
Louis, MO).
Induction of cytokines and ELISAs
To induce IL-12 production from macrophages, the
established and primary macrophage cells were pre-
treated with 1000 U/ml of IFN-g for 8 h before LPS
addition (5 mg/ml). After 30 h of LPS stimulation, the
supernatants were harvested and the amount of IL-12 or
TNF-a secreted from activated macrophages was quan-
ified with ELISA kits (R&D Systems). Results are ex-pressed as pg/ml, based on recombinant cytokine stan-
dards.
Analysis of NO accumulation
NO accumulation by activated macrophage cells was
determined as previously reported (Ding et al., 1988).
Briefly, 100 ml of supernatant was combined with an
equal volume of Griess reagent, and the samples were
incubated at room temperature before measuring the
absorbance at 550 nm. Using the standard curve, the
absorbance of the sample was converted to the mmol of
NO.
Measurement of IL-12 p40 promoter activity
A 3.6-kb genomic DNA fragment of the human IL-12
p40 promoter (23600 to 154) was isolated from l-phage
genomic clone (Lambda Fix Library; Stratagene, La Jolla,
CA), and then cloned into a plasmid encoding luciferase
gene, pGL2-control (Promega), at BamHI and XhoI sites
by replacing with its original SV40 early promoter to
obtain IL-12 p40 promoter-luciferase construct. This pro-
moter-reporter plasmid was designated as pGL2-IL-12
p40/Luc. To measure promoter activity, RAW 264.7/Neo
and RAW 264.7/Core were transiently cotransfected with
20 mg of the IL-12 p40-luciferase construct and 5 mg of a
plasmid containing b-galactosidase under the control of
CMV promoter (electroporation at 960 mF and 250 V). The
transfected cells were incubated for 16 h at 37°C in 5%
CO2 atmosphere and treated with 1000 U/ml of recombi-
nant IFN-g for 8 h before the addition of LPS (5 mg/ml).
After 8-h stimulation with LPS, cells were harvested and
lysed with 100 ml of lysis buffer (20 mM HEPES, pH 7.2,
150 mM NaCl, 1% Triton X-100, 10% glycerol). Lysates
were used for both luciferase and b-galactosidase as-
say. Lysates were mixed with equal volumes of assay
buffer (50 ml) containing 1 mM luciferin (Promega), and
luciferase activity was measured as light units using a
luminometer (Luminol). b-Galactosidase expression was
assayed using an assay buffer [1 mg/ml of CPRG (BMB),
1 mM MgCl2, 100 mM DTT, and 20 mM Tris–HCl, pH 7.2].
Luciferase expression was corrected based on the si-
multaneous expression of b-galactosidase.
Preparation of splenic DCs from transgenic mice
carrying HCV core gene
The transgene construct, pRc/CMV-HBVCore, which
encodes the core gene under the control of a transcrip-
tional regulatory region from hepatitis B virus, was intro-
duced into FVB mouse embryos. Mice were maintained
in a specific pathogen-free state. The transgenic mice
lineage was screened by PCR and Southern blot analy-
ses. The expression of core protein from various tissues
was tested by immunoblotting with anticore antibody.
Nontransgenic littermate mice that showed no expres-
sion of core protein were used as negative controls.
a
c
n
S
b
p
u
w
M
e
h
s
w
a
b
2
B
c
h
m
a
c
s
o
S
t
s
M
t
p
C
a
m
c
a
B
B
C
C
C
C
C
D
D
D
D
F
F
278 LEE ET AL.Splenic DCs of both transgenic and nontransgenic mice
were prepared as previously described (Ridge et al.,
1996; Singh et al., 1998). Briefly, splenocytes adhered to
tissue culture plates for 2 h, after which nonadherent
ells were removed. Adherent cells were cultured over-
ight in 5 ng/ml of recombinant mouse GM-CSF (R&D
ystems) to differentiate into DCs. After 12 to 16 h incu-
ation, the weakly adherent cells were harvested and
urified again with 55% Percoll density-gradient centrif-
gation. The resulting low-density cells from interface
ere used as splenic DCs-enriched populations.
ixed lymphocyte reaction
To evaluate the allostimulatory capacity of HCV core-
xpressing THP-1 cells, MLR was performed. PBMC of
ealthy donors were obtained by Ficoll–Hypaque den-
ity-gradient centrifugation. These cells were incubated
ith mouse anti-human CD3 antibody (10 mg/106 cells)
nd magnetic bead-tagged goat anti-mouse IgG anti-
ody to collect primary human T cells. After IFN-g (1000
U/ml, 8 h) treatment and LPS (5 mg/ml, 24 h) stimulation,
THP-1/neo or THP-1/core 1–191 was inactivated with
mitomycin C (50 mg/ml, 40 min). The inactivated cells
(2 3 106 cells/well) were placed on 96-well flat-bottom
culture plates and mixed with primary CD31 T cells (1 to
3 106 cells/well) and cocultured for 5 days. Cells were
pulsed with [3H]thymidine (1 mCi/well) for 18 h before
being harvested, and then the amounts of [3H]thymidine
incorporated into cells were measured with a beta
counter. The supernatants from MLR were harvested at
Day 5 and assayed to measure the production of IFN-g
and IL-10 through ELISA.
Purification of HCV core protein produced in E. coli
A plasmid expressing HCV core gene (type 1a, amino
acids 1–191), pET-3a/core191, was introduced into E. coli
L21(DE3). The expression of HCV core gene in cultured
ells was induced by the addition of 0.5 mM IPTG. The
arvested cells were resuspended in column buffer (20
M sodium phosphate, pH 7.0, 1 mM DTT, 1 mM EDTA)
nd disrupted by sonication. After centrifugation of the
ell lysates, the precipitated insoluble proteins were dis-
olved in column buffer containing 8 M urea and loaded
nto a column packed with a cation exchanger resin,
P–Sepharose Fast Flow (Pharmacia, Piscataway, NJ). At
he end of sample loading, the column was washed and
electively eluted with column buffer containing 0.1 to 1
NaCl in stepwise manner. To renature the core pro-
ein, urea was gradually removed through dialysis. The
urity of the obtained protein was over 95%, based on the
oomassie blue staining. The circular dichroism spectral
nalysis of the purified core protein showed that esti-
ated compositions of the secondary structure coin-ided with the predicted pattern, based on their amino
cid sequences (manuscript in preparation). In addition,the in vitro binding assay (Hsieh et al., 1998) demon-
strated that the purified GST-hnRNP K efficiently inter-
acted with the core protein, but not with the heat-inacti-
vated core protein (boiled for 10 min).
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